Advisory boards

OEDES

The Oncode Exploratory Development Expert Support (OEDES) team provides guidance and advice when it comes to translating our fundamental scientific insights into new diagnostics and therapeutic strategies. Together with our scientists, OEDES optimizes the design of the most efficient and effective (pre-) clinical strategy for an early assessment of the benefit profile of our inventions. This includes the definition of a quantitative Target Product Profile ("How good should it be") and associated Proof of Concept (PoC) decision criteria as well as the identification of biomarkers with relevant predictive value.

OEDES has extensive experience in Exploratory Development in both major Pharma's as well as in small biotech across a large range of indication areas. OEDES consists of the following members:

Danny Burg

Danny Burg

OEDES member

Danny is a European Registered Toxicologist and has 20 years of experience in oncology drug development, which includes research positions at the Netherlands Cancer Institute and Leiden University, and several positions within the pharmaceutical industry. In 2018 he co-founded D2Team, a consultancy company that provides non-clinical development services for the pharma/biotech industry. His experience covers bioanalysis, drug metabolism and biomarkers, and nonclinical toxicology support for small molecules and biologicals in all phases of drug development.

Get In Touch:


OEDES member
Ellen Hulskotte

Ellen Hulskotte

OEDES member

Ellen Hulskotte has 20+ years of international pharmaceutical industry experience and a deep insight in preclinical and clinical drug development. As a global clinical pharmacology lead for projects in early and late phases of development she has designed and executed innovative clinical development plans and studies to milestones and budgets. She authored various clinical and regulatory documents and successfully interacted with regulatory authorities in Europe, US and Japan in writing and face-to-face. In 2018, Ellen became partner of Curare Consulting BV, a consulting company specialized in early clinical drug development of amongst others oncology compounds. Before, Ellen held several senior scientific and/or leadership positions at Merck Sharp & Dohme (MSD), Schering-Plough and Organon, and was the clinical lead at Treeway - a biotech company aiming to develop therapies for ALS. Ellen became a registered Clinical Pharmacologist at the Centre of Human Drug Research (CHDR) in Leiden and earned her PhD in Biomedical Science at the Erasmus University Rotterdam (EUR) on HIV vaccine development.

Get In Touch:


OEDES member
Sophie Gerritse

Sophie Gerritse

OEDES member

Sophie Gerritse is PhD student medical oncology. After completing her medical school at the ‘Vrije Universiteit Amsterdam’ she started in 2013 as a resident ‘Internal Medicine’ in the Rotterdam Region (Amphia Ziekenhuis Breda, Sint Fransiscus Rotterdam). Aiming to become a medical oncologist and with the current significant advances in basic and applied cancer research, she decided to pause her residency program to attend a full-time PhD-program within the medical oncology under the supervision of prof. dr. H.M.W. Verheul (Amsterdam-UMC, location VUmc and Radboud UMC Nijmegen). She is the study coordinator of several (Phase I, II) clinical studies with the main focus to optimize therapy with targeted agents in metastatic (colorectal) cancer. She has experience in the design, set-up and management of clinical trials and translation of pre-clinical results. In 2021 she will continue her residency in the Erasmus Medical Center in Rotterdam.

Get In Touch:


OEDES member
Emil Pot

Emil Pot

Business Development

With an educational background in law, Emil has gained over 25 years of experience as a patent attorney and business developer. In his capacity as business development manager at the Flemish Institute for Biotechnology (VIB) he drafted and negotiated licensing, R&D and IP agreements and helped creating two start-up companies. He joined ActoGeniX as general counsel and was responsible for all business development, legal and IP matters. The company raised a total of €45MM in three consecutive financing rounds. Emil is a registered patent attorney, does business development for NLO and acts as CEO of Allero Therapeutics. At Oncode Emil helps to translate fundamental research to the market by developing and executing IP strategies, advising and assisting in company creation and building and maintaining stakeholder relations.


Business Development